岩藻多糖联合含铋剂四联疗法治疗幽门螺杆菌相关性胃炎的研究进展

DOI：10.16424/j.cnki.cn32-1807/r.2025.05.018

[中图分类号]R573.3 [文献标志码]A [文章编号] 1674-7887（2025）05-0491-04

Progress on fucoidam combined with bismuth-containing quadruple therapy for Helicobacterpyloriassociatedgastritis*

WEIFet 1** ，SHAOJianguo 2*** ，CHENLin²，ZHANGYujiao² （Medical School of NantongUniversity，Jiangsu 226001; 2Department of Gastroenterology，Nantong Third Hospital Afiliated to Nantong University）

[Abstract]Helicobacterpylori（Hp）infectionisasignificantcauseofdigestivetractdiseases，suchaschronicgastritis，peptic ulcers，and gastriccancer.Thebismuth-containingquadrupletherapy，acommonclinical appoach toeradicateHp，has limitations suchasgastrointestinalreactions andtheriskofdrugresistane，whichcanreducepatientcomplianceand afecttreatmentoutcomes.Recent studieshaveshown that fucoidan，anaturalactivesubstancederived frombrownalgae，exhibits significantvalueinHpinfectiontreatmentduetoitsuniqueanti-adhesionproperties，immuneregulatoryfunctions，andsyergistic antibacterialeffects.Thisarticlesystematicallyreviewstheclinicaleficacyandsafetyevidenceoffucoidancombinedwith bismuth-containingquadrupletherapyfor Hp-asociatedgastritis，focusingonitsenhancedeficacyinimproving pathogen clearance，reducing mucosal damage，andloweringtheincidenceofadversereactions，aimingtoprovidenew insightsintootimizing Hp infection treatment regimens.

[KeyWords]Helicobacterpylori; Helicobacterpylori-asociatedgastritis;fucoidan;bismuthcontainingquadrupletherapy; drug safety

幽门螺杆菌（Helicobacterpylori，Hp）感染是引发慢性胃炎、胃溃疡等胃肠疾病的重要病因。（剩余8228字）